Germany's Merck KGaA Shares Jump After Guidance Lift
By Adria Calatayud
Shares in Germany's Merck KGaA leapt after the company lifted its full-year sales and earnings guidance, citing strong momentum in its life-sciences business.
In European midday trading Wednesday, shares in Merck were up 8.2%, recovering from most of their year-to-date losses.
In its first quarterly update since Kai Beckmann became the group's chief executive, Merck raised its full-year guidance, saying it expects the performance of its life-science and healthcare businesses to be better than previously anticipated.
The company--with operations spanning lab equipment, pharmaceuticals and chemicals--forecast net sales to range from 20.4 billion to 21.4 billion euros ($23.95 billion to $25.13 billion) this year. This compares with its previous expectations of 20 billion to 21.1 billion euros.
Merck anticipates organic sales growth of up to 3%, against previous guidance that ranged from a 1% fall to a 2% rise.
Earnings before interest, taxes, depreciation and amortization excluding one-time items--the company's preferred profit metric--is forecast at between 5.7 billion and 6.1 billion euros, Merck said. This compares with a previous outlook of 5.5 billion to 6 billion euros.
The company said the change mainly reflected its expectations of stronger momentum in its life-sciences unit and greater resilience in its healthcare division amid challenges. Merck's pharma business has been hit by the U.S. patent expiration of multiple-sclerosis drug Mavenclad, which used to be the division's best-selling product.
For the first quarter, Merck posted an after-tax profit of 669 million euros, down 9.4% on year.
Sales were 5.13 billion euros, up 2.9% organically, and Ebitda before one-time items was broadly flat at 1.53 billion euros.
Analysts had forecast sales at 5.1 billion euros and Ebitda before one-time items at 1.46 billion euros, according to consensus estimates provided by the company.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
May 13, 2026 06:19 ET (10:19 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
